Nektar Therapeutics — 2014 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014. The filing also reports fourth-quarter results. Figures are in U.S. dollars unless noted. This is a biopharmaceutical company developing proprietary medicines using PEGylation and advanced polymer-conjugate technologies, alongside partner licensing, manufacturing and supply programs.
Financial performance and position
| Metric | FY 2014 | FY 2013 | Change / context |
|---|---|---|---|
| Total revenue | $200.7 million | $148.9 million | Up 35%; driven principally by collaboration and milestone revenue. |
| Product sales | $25.2 million | $44.8 million | Down 44%, attributed mainly to lower partner demand. |
| License, collaboration and other revenue | $153.3 million | $80.9 million | Up 90%; included $105.0 million of AstraZeneca milestones recognized in 2014. |
| Net loss | $53.9 million | $162.0 million | Improved substantially, but the company remained loss-making. |
| Net loss per share | $0.42 | $1.40 | Basic and diluted. |
| Operating cash flow | $(142.0) million | $(38.5) million | Cash use increased, reflecting operating needs and timing of milestone receipts. |
| Cash, cash equivalents and investments | $262.8 million | $262.0 million | Includes $25.0 million of restricted cash at year-end 2014. |
| Working capital | $224.2 million | $159.7 million | Improved year over year. |
| Indebtedness | $151.8 million | Not clearly stated in the selected data | Includes $125.0 million of 12% senior secured notes due July 2017; excludes the royalty-sale liability. |
- Operating loss was $16.5 million, versus $120.1 million in 2013. Product gross loss was $3.4 million and product gross margin was negative 13%, versus a 14% margin in 2013. Management cited a fixed-price supply arrangement priced below fully burdened manufacturing cost and a less favorable sales mix.
- Revenue included $21.9 million of non-cash royalty revenue related to the 2012 sale of CIMZIA and MIRCERA royalty rights. Related non-cash interest expense was $20.9 million; the $120.5 million year-end royalty obligation is recorded as a liability and, the company says, will not be settled in cash.
- Quarter four 2014 revenue was $19.6 million and net loss was $45.7 million. Quarter four 2013 revenue was $31.1 million and net loss was $47.7 million. Results fluctuate significantly with milestone timing.
- Interest expense was $17.9 million, in addition to the non-cash royalty-related interest expense. Senior notes carry a 12% coupon and are secured by substantially all company assets.
Material changes and business developments
- MOVANTIK (naloxegol) became Nektar’s first proprietary drug candidate to receive approval: FDA approval for opioid-induced constipation in September 2014 and European Commission authorization in December 2014. AstraZeneca planned U.S. launch for late Q1 2015 and European launch in the second half of 2015.
- 2014 collaboration revenue included a $35 million FDA-approval milestone and recognition of a previously refundable $70 million AstraZeneca payment after FDA approval removed the repayment contingency. The company also recognized $8 million of BAX 855 milestones following positive Phase 3 results.
- R&D expense fell 22% to $147.7 million, mainly as the BEACON study approached completion and the NKTR-181 Phase 2 study ended. FY 2013 included an $11.3 million SUNY settlement charge.
- The company raised approximately $117.2 million net from a January 2014 common-stock offering and issued 9.775 million shares. Shares issued and outstanding rose to 131.2 million at year-end from 116.5 million.
- Revenue concentration increased: AstraZeneca, UCB and Roche represented 52%, 16% and 11% of FY 2014 revenue, respectively.
Outlook, risks and contingencies
- Management estimated that available working capital would fund current plans for at least 12 months from year-end 2014. It nevertheless expected operating cash use and R&D expense to increase in 2015, particularly as NKTR-181 Phase 3 studies begin; the program is expected to require substantial investment over two to three years.
- Management expected product sales and product gross margin to increase in 2015, subject to partner demand and product mix. It also expected cash royalties to rise if AstraZeneca launched MOVANTIK. Up to $140 million of MOVANTIK launch milestones remained contingent on first commercial sales in the U.S. and a major EU country; timing and achievement were not assured.
- Top-line BEACON Phase 3 results for etirinotecan pegol were expected in March 2015. A successful study could lead Nektar to pursue U.S. commercialization itself, requiring investment in sales and marketing infrastructure; failure could materially affect the program’s value.
- Other key development programs included NKTR-181 Phase 3 for chronic pain, partner-led BAX 855 (BLA filed), and Bayer’s Phase 3 Amikacin Inhale program. NKTR-214 was planned to enter Phase 1 in the second half of 2015. These programs remain exposed to clinical, regulatory, manufacturing and funding uncertainty.
- Key risks include reliance on a small number of partners for revenue and commercialization; clinical-trial failure or delay; substantial cash needs and potential future financing or dilution; manufacturing and single-source supply constraints; patent and collaboration disputes; and competition, reimbursement and market-acceptance uncertainty.
- The 12% notes impose operating restrictions and cash covenants. The $25 million restricted cash reserve was scheduled to be released July 1, 2015; thereafter, subject to conditions, unrestricted cash and cash equivalents must not fall below $25 million at quarter-end for any two consecutive quarters through June 2017.
- Nektar filed a January 2015 contract action against Allergan and MAP over claimed unpaid economic-sharing amounts related to SEMPRANA. It also disclosed German patent litigation in which Bayer seeks co-ownership rights in certain PEGylated Factor VIII patent filings. A prior SUNY settlement required $12 million in installments.
- OMONTYS was voluntarily recalled in 2013 after reports of serious hypersensitivity reactions, including deaths; Affymax terminated its agreement with Nektar in July 2013. The filing says no proceedings were then believed likely to have a material adverse effect, but litigation and indemnification exposures are inherently uncertain.
Important facts for investors to verify
- Whether and when AstraZeneca launched MOVANTIK/MOVENTIG, and the resulting launch milestones, sales, royalties and post-marketing study costs.
- Final BEACON results and subsequent regulatory or partnering decisions for etirinotecan pegol; the filing’s March 2015 data expectation was forward-looking.
- Cash burn, unrestricted liquidity, covenant compliance and financing needs as NKTR-181 and other programs advance.
- Progress and economics of partner-led BAX 855 and Amikacin Inhale, including manufacturing obligations and potential milestones or royalties.
- Revenue quality and concentration: distinguish cash receipts from non-cash royalty revenue and milestone recognition, and assess dependence on AstraZeneca, UCB and Roche.
- Potential dilution, debt service and outcomes of the Allergan/MAP dispute and Bayer patent litigation.
Reporting note: The filing reports substantial losses and negative operating cash flow despite improved FY 2014 earnings. Management identified no formal numerical earnings or revenue guidance in the supplied filing text. The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting as of December 31, 2014.